MBRC-101, an EphA5-targeting ADC with efficacy in models of breast cancer

Dec. 28, 2023

Researchers from Mbrace Therapeutics Inc. presented the discovery and preclinical evaluation of MBRC-101, a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5, being developed for the treatment of cancer.

BioWorld Science Conferences San Antonio Breast Cancer Symposium Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Photo of scale with woman sitting on floor holding head and arms on knees

Rethinking anorexia: A disorder of mind and metabolism

BioWorld Science

Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...